RNF43 and neoplasm: In preclinical models, RXC004 reduced tumor growth and increased differentiation in Wnt-dependent RNF43-mutant pancreatic AsPC1 and HPAF-II and RSPO3-fusion SNU-1411 colorectal xenografts [430].